Understanding Your ATP13A2 Diagnosis

If you or your loved one has recently been diagnosed with a condition related to the ATP13A2 gene, you may feel as though you are navigating a maze of different names and medical terms. You might have heard your doctor use terms like CLN12, Kufor-Rakeb syndrome, or SPG78 ^[1]. It is common for patients and families to feel confused by these labels, especially when searching for information online.

The most important thing to understand is that these names describe related phenotypes associated with the same underlying genetic cause: pathogenic variants (changes in the DNA sequence) in the ATP13A2 gene ^[2]. Doctors now view these as a clinical continuum (a spectrum), meaning the same genetic variant can look different from person to person ^[1]. Receiving this diagnosis is often the end of a long “diagnostic odyssey,” and while the names are complex, they finally provide a roadmap for your care.

One Gene, Many Names

Because this condition is so rare, different groups of doctors originally discovered it in different ways and gave it different names based on the symptoms they saw first. They are not strictly interchangeable, but rather describe where a patient falls on the spectrum.

• CLN12 (Neuronal Ceroid Lipofuscinosis 12): This name is used when the condition is classified as a lysosomal storage disorder. It refers to the buildup of a waste material called lipofuscin (a fatty pigment) inside the body’s cells ^[3].
• Kufor-Rakeb Syndrome (KRS): Named after the village in Jordan where it was first described, this term is often used when the primary symptoms are parkinsonism (tremors, stiffness, and slow movement) starting in childhood or adolescence ^[4][2].
• SPG78 (Hereditary Spastic Paraplegia 78): This label is typically used when the main symptom is spasticity (muscle stiffness) that primarily affects the legs and makes walking difficult ^[1][5].

Regardless of the name used, the core of the condition is the same: the ATP13A2 gene is not working correctly ^[1].

Why the ATP13A2 Gene Matters

The ATP13A2 gene provides instructions for making a protein that research suggests acts like a “gatekeeper” or “pump” in the lysosome—the recycling center of your cells ^[6].

Under normal conditions, this protein is believed to pump certain substances (called polyamines) out of the lysosome so the cell can stay healthy ^[7]. When the gene has a pathogenic variant, altered protein function means this pump doesn’t work correctly. Laboratory studies suggest this leads to several problems inside the cell:

• Recycling failure: Waste products build up inside the lysosome, which research suggests may eventually cause it to “leak” or break ^[8][6].
• Energy issues: The “powerhouses” of the cell, called mitochondria, can become stressed or damaged ^[9].
• Protein buildup: A protein called alpha-synuclein (often associated with Parkinson’s disease) can clump together in the brain cells because the recycling system can’t clear it away ^[10][8].
  It is important to note that these mechanisms are still being actively researched.

An Exceptionally Rare Journey

If you feel like you are one of the only people in the world with this diagnosis, you are very nearly correct. ATP13A2-related disorders are considered ultra-rare.

Because the condition is so infrequent, there are no exact numbers on how many people have it worldwide. Most of what doctors know comes from small groups of patients ^[11]. For example:

• One research study identified only about 69 confirmed cases with pathogenic biallelic variants matching the Kufor-Rakeb syndrome pattern globally in a recent review ^[11].
• In a large study of patients with spasticity (HSP), only about 0.7% were found to have pathogenic biallelic ATP13A2 variants ^[5].

What This Means for You

Because this is a spectrum, your experience may not look exactly like the descriptions you find in medical textbooks. Some people have mostly movement issues (parkinsonism), while others have mostly walking issues (spasticity) or changes in thinking and memory ^[12][13].

Your medical team will likely focus on managing your specific symptoms rather than treating the “name” of the disease. This “gene-first” approach ensures that even if your symptoms shift over time, your doctors understand the root cause of what is happening in your cells ^[1]. Finding a neurologist or a genetics specialist who is familiar with lysosomal storage disorders or rare movement disorders is often the most helpful next step.